Testosterone Extremes and Atrial Fibrillation Risk Converge at Both Ends of the Curve
A review in JAMA suggests that both low and high testosterone in men may be associated with a higher risk of atrial fibrillation. The signal is clinically important because it runs against the older habit of thinking about sex hormones in simple linear terms, where only deficiency or only excess would be expected to matter. Instead, the review points toward a U-shaped relationship in which deviation in either direction may coincide with electrical instability in the atria.
That framing has immediate bedside relevance. Atrial fibrillation remains one of the most common sustained arrhythmias in adult practice, and even modest shifts in risk can matter when they are distributed across large populations of men undergoing hormone testing, endocrine evaluation, or treatment for symptoms that may prompt testosterone assessment in the first place.
Why Hormone Extremes Could Matter for Atrial Electrophysiology
Testosterone influences multiple physiologic systems that intersect with arrhythmia biology. It affects vascular tone, autonomic balance, body composition, and metabolic signaling, all of which can shape atrial substrate over time. When testosterone is too low, downstream changes in inflammation, adiposity, insulin sensitivity, and cardiovascular fitness may contribute to a milieu in which atrial remodeling becomes more likely. When testosterone is too high, the concern shifts toward a different form of physiologic stress, with potential effects on hemodynamics, electrophysiologic stability, and the broader cardiovascular system.
The practical value of a review like this lies in pattern recognition. A single hormone value does not explain atrial fibrillation on its own, and it should never replace standard evaluation for structural heart disease, hypertension, sleep-disordered breathing, thyroid dysfunction, alcohol exposure, or age-related risk. Even so, the finding that both ends of the testosterone spectrum may align with greater atrial fibrillation risk encourages clinicians to think more carefully about hormonal context rather than chasing a simplistic threshold.
Men evaluated for hypogonadal symptoms often present with fatigue, reduced libido, mood change, or loss of muscle mass, and testosterone testing can become part of the workup. Men receiving androgen therapy may also be monitored over time for safety and symptom response. In both settings, arrhythmia risk belongs in the conversation, especially when symptoms such as palpitations, reduced exercise tolerance, or intermittent dyspnea appear after hormone changes or dose adjustments.
A U-Shaped Signal Carries Different Meaning Than a Threshold Effect
The key clinical message is not that testosterone is uniformly dangerous or uniformly protective. It is that cardiovascular electrophysiology may respond poorly when hormone levels move too far in either direction. A U-shaped association is often a sign that physiology depends on balance, not maximal replacement or maximal suppression.
This matters because testosterone is not an isolated laboratory value. It sits inside a network that includes pituitary regulation, gonadal function, inflammatory signaling, and cardiometabolic health. Low testosterone can reflect chronic illness, obesity, or age-related endocrine change. High testosterone can reflect exogenous exposure, biologic variation, or other endocrine states. Each scenario may carry a distinct arrhythmic profile, even if the end point looks the same on an electrocardiogram.
Atrial fibrillation also has a habit of revealing underlying disease rather than appearing in isolation. Any hormonal association should therefore be interpreted as one piece of a broader risk architecture. In practice, that means the finding should prompt more thoughtful monitoring, not reflexive hormonal intervention.
What Clinicians Should Do with This Signal
The most responsible response is clinical caution, not therapeutic overreaction. Testosterone testing should still be interpreted in the full context of symptoms, comorbid illness, age, and medication exposure. When testosterone is measured, the result should not be treated as a stand-alone explanation for arrhythmia risk. Instead, it can inform a broader assessment that includes cardiovascular history, blood pressure, body weight, sleep quality, and prior episodes of palpitations or irregular pulse.
For patients already diagnosed with atrial fibrillation, any discussion of testosterone should be deliberate. For patients receiving testosterone therapy, new palpitations or documented rhythm changes should not be dismissed as incidental. The same holds for men with unexpectedly high endogenous levels, in whom arrhythmia risk may deserve closer attention if other cardiovascular factors are present.
This review also reinforces a broader endocrine principle: replacement therapy is most defensible when it restores physiologic balance, not when it pushes a biomarker toward the edge of normal. A therapy that overshoots can create a different problem than the deficiency it was meant to correct.
What the Review Does Not Prove
Association is not causation. A review can identify a consistent pattern across studies, but it cannot by itself prove that testosterone levels directly trigger atrial fibrillation. Confounding is a real concern, particularly because testosterone levels can mirror overall health status, obesity, frailty, chronic disease burden, and other variables that also affect cardiovascular risk.
The abstract available here does not provide the number of studies included, the population mix, the magnitude of risk, dose-response details, or whether the pattern was observed consistently across different forms of testosterone measurement. Those details would shape how strongly the finding should influence practice. In their absence, the safest interpretation is measured and provisional: both low and high testosterone may mark a higher-risk state for atrial fibrillation, but the biology and the clinical direction of effect remain incompletely defined.
Still, the signal is hard to ignore. When endocrine testing and arrhythmia risk point in the same direction, even at opposite ends of the hormone spectrum, clinicians are left with a useful reminder: cardiovascular risk does not always move in a straight line.